Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		035879-0116	09/756,293
INFORMATION DISCLOSURE CITATION		APPLICANT	
		Thomas E. WAGNER et al.	
		FILING DATE	GROUP ART UNIT
(Use several sheets if necessary)		01/09/2001	1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	A1	4,762,701	08/88	HORAN et al.	424	1.1	
	A2	4,783,401	11/88	HORAN et al.	435	34	
	A3	4,859,584	08/89	HORAN et al.	435	29	

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	A4	PARKINSON *et al.*, "Cytokines: Biology And Applications In Cancer Medicine", *in* CANCER MEDICINE, 4th ed., pp. 1213-1226
	A5	PHILIP *et al.*, "Treatment Of Malignant Melanoma With Interleukin-2", *Seminars in Oncology*, Vol. 24(1):S4-32--S4-38, (1997
	A6	SMITH et al., "Immune And Gene Therapy For Melanoma, And The Immunobiology Of Melanoma", *International Journal Of Dermatology*, Blackwell Science Ltd., Vol. 38:490-508, (1999)
	A7	BOON et al., "Tumor Antigens Recognized By T Cells", Elsevier Science Ltd., Vol.18:267-268, (1997)
	A8	STOCKERT et al., "A Survey Of The Humoral Immune Response Of Cancer Patients To A Panel Of Human Tumor Antigens", *J. Exp. Med.,* The Rockefeller University Press, Vol. 187(8):1349-1354, (1998)
	A9	SAHIN et al., "Human Neoplasms Elicit Multiple Specific Immune Responses In The Autologous Host", *Proc. Natl. Acad. Sci. USA,* Immunology, Vol. 92:11810-11813, (1995)
	A10	GABRILOVICH et al., "Production of Vascular Endothelial Growth Factor By Human Tumors Inhibits The Functional Maturation Of Dendritic Cells", *Nature Medicine,* Vol. 2(10):1096-1103, (1996)
	A11	ISHIDA et al., "Defective Function Of Langerhans Cells In Tumor-Bearing Animals Is The Result Of Defective Maturation From Hemopoietic Progenitors", *The Journal of Immunology*, The American Association of Immunologists, pp. 4842-4851, (1998)
	A12	STEINMAN, "The Dendritic Cell System And Its Role In Immunogenicity", *Annu. Rev. Immunol.*, Annual Reviews Inc., Vol. 9:271-296, (1991)
	A13	MACATONIA et al., "Primary Stimulation By Dendritic Cells Induces Antiviral proliferative And Cytotoxic T Cell Responses In Vitro", *J. Exp. Med.*, The Rockefeller University Press, Vol. 169:1255-1264, (1989)

EXAMINER D James Li **DATE CONSIDERED** 4/9/02

* **EXAMINER: Initial if citati n considered, whether or not citation is in c nformance with MPEP 609; Draw lin through citation if not in conformance and not consider d. Include any copy f this form with next communicati n t applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 035879-0116	SERIAL NO. 09/756,293
INFORMATION DISCLOSURE CITATION		APPLICANT Thomas E. WAGNER et al.	
(Use several sheets if necessary)		FILING DATE 01/09/2001	GROUP ART UNIT 1632

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

A14	MEHTA-DAMANI et al., "Generation Of Antigen-Specific CD8+ CTLs From Naïve Precursors", *The Journal Of Immunology*, The American Association Of Immunologists, Vol. 153:996-1004, (1994)
A15	PORGADOR et al., "Bone Marrow-Generated Dendritic Cells Pulsed With A Class I-Restricted peptide Are Potent Inducers Of Cytotoxic T Lymphocytes", *J. Exp. Med.*, The Rockefeller University Press, Vol. 182:255-260, (1995)
A16	YOUNG et al., "Dendritic Cells As Adjuvants For Class I Major Histocompatibility Complex-Restricted Antitumor Immunity", *J. Exp. Med.*, The Rockefeller University Press, Vol. 183:7-12, (1996)
A17	MAYORDOMO et al., "Bone Marrow-Derived Dendritic Cells Pulsed With Synthetic Tumour Peptides Elicit Protective And Therapeutic Antitumour Immunity", *Nature Medicine*, Vol. 1(12):1297-1303, (1995)
A18	BAKKER et al., "Generation Of Antimelanoma Cytotoxic T Lymphocytes From health Donors After Presentation of melanoma-Associated Antigen-Derived Epitopes by Dendritic Cells in Vitro", *Cancer Research*, Vol. 55:5330-5334, (1995)
A19	FLAMAND et al., "Murine Dendritic Cells pulsed In Vitro With Tumor Antigen Induce Tumor Resistance In Vitro", *Eur. J. Immunol.*,, VCH Verlagsgesellschaft mbH, Vol. 24:605-610, (1994)
A20	GONG et al., "Induction Of Antigen-Specific Antitumor Immunity With Adenovirus-Transduced Dendritic Cells", *Gene Therapy*, Stockton Press, Vol. 4:1023-1028, (1997)
A21	SONG et al., "Dendritic Cells Genetically Modified With An Adenovirus Vector Encoding The cDNA For A Model Antigen Induce Protective And Therapeutic Antitumor Immunity", *J. Exp. Med.*, The Rockefeller University Press, Vol. 186(8):1247-1256, (1997)
A22	SPECHT et al., "Dendritic Cells Retrovirally Transduced With A Model Antigen Gene Are Therapeutically Effective Against Established Pulmonary Metastases", *The Journal Of Experimental Medicine*, Vol. 186(8):1213-1221, (1997)
A23	ROSENBERG et al., "Immunologic And Therapeutic Evaluation Of A Synthetic Peptide Vaccine For The Treatment of Patients With Metastatic Melanoma", *Nature Medicine*, Vol. 4(3):321-327, (1998)
A24	WALLACK et al., "A Phase III Randomized, Double-Blind, Multiinstitutional Trial Of Vaccinia Melanoma Oncolysate-Active Specific Immunotherapy For Patients With Stage II Melanoma", *Cancer*, Vol. 75(1):34-42, (1995)
A25	BYSTRYN, "Clinical Activity of A Polyvalent Melanoma Antigen Vaccine", Springer-Verlag Berlin, Vol. 139:337-348, (1995)

EXAMINER	**DATE CONSIDERED** 4/9/02

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		035879-0116	09/756,293
INFORMATION DISCLOSURE CITATION		APPLICANT	
		Thomas E. WAGNER et al.	
		FILING DATE	GROUP ART UNIT
(Use several sheets if necessary)		01/09/2001	1632

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

A26	MITCHELL, "Perspective On Allogeneic Melanoma Lysates In Active Specific Immunotherapy", *Seminars In Oncology*, Vol. 25(6):623-635, (1998)
A27	MORTON et al., "Polyvalent Melanoma Vaccine Improves Survival Of Patients With Metastatic Melanoma", *Ann. N.Y. Acad. Sci,.Vol.* 690:120-134 (1993);
A28	BERD et al., "Autologous, Hapten-Modified Vaccine As A Treatment For Human Cancers", *Seminars in Oncology*, Vol. 25(6):646-653, (1998)
A29	BERD et al., "Autologous Hapten-Modified Melanoma Vaccine As Postsurgical Adjuvant Treatment After Resection Of Nodal Metastases", *Journal Of Clinical Oncology*, Vol. 15(6):2359-2370, (1997)
A30	SHURIN, "Dendritic Cells Presenting Tumor Antigen", *Cancer Immunol. Immunother*, Vol. 43:158-164, (1996)
A31	HAIGH et al., "Vaccine Therapy For patients With Melanoma", *Oncology*, Vol. 13(11):1561-1574, (1999)
A32	GONG et al., "Induction Of Antitumor Activity By Immunization With Fusions Of Dendritic And Carcinoma Cells", *Nature Medicine*, Vol. 3(5):558-561, (1997)
A33	WANG et al., "Eliciting T Cell Immunity Against Poorly Immunogenic Tumors By Immunization With Dendritic Cell-Tumor Fusion Vaccines", *The Journal Of Immunology*, The American Association of Immunologists, Vol. 161:5516-5524, (1998)
A34	LESPAGNARD et al., "Dendritic Cells Fused With Mastocytoma Cells Elicit Therapeutic Antitumor Immunity", *Int. J. Cancer*, Vol. 76:250-258, (1998)
A35	ROWSE et al., "Tolerance And Immunity To MUC1 In A Human MUC1 Transgenic Murine Model", *Cancer Research*, Vol. 58:315-321, (1998)
A36	ABBAS et al., "Cellular and Molecular Immunology", Saunders Text and Review Series, pp. 347-350
A37	WEI et al., "Long-Term Expression Of Human Growth Hormone (hGH) In Mice Containing Allogeneic Yolk Sac Cell Derived Neovascular Implants Expressing hGH", *Stem Cells*, Vol. 14:2320238, (1996)
A38	HORAN et al., "Stable Cell Membrane Labelling", *Nature*, Vol. 340:167-168, (1989)

EXAMINER	**DATE CONSIDERED**
	4/9/02

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if n t in conformanc and not c nsidered. Include any c py f this f rm with next communication t applicant.**

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 035879-0116	SERIAL NO. 09/756,293
INFORMATION DISCLOSURE CITATION *(Use several sheets if necessary)*		APPLICANT Thomas E. WAGNER et al.	
		FILING DATE 01/09/2001	GROUP ART UNIT 1632

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

A39	HORAN et al., "Fluorescent Cell Labeling For In Vivo And In Vitro Cell Tracking", *Methods In Cell Biology*, Academic Press, Inc., Vol. 33:469-491, (1990)
A40	MICHELSON et al., "In Vivo Tracking Of Platelets: Circulating Degranulated Platelets Rapidly Lose Surface P-Selectin But Continue To Circulate And Function", *Proc. Natl., Acad. Sci. USA, Vol. 93:11877-11882, (1996)*
A41	ZITVOGEL et al., "Therapy Of Murine Tumors With Tumor Peptide-Pulsed Dendritic Cells: Dependence On T Cells, B7 Costimulation, And T Helper Cell 1-Associated Cytokines", *J. Exp. Med.*, The Rockefeller University Press, Vol. 183:87-97, (1996)
A42	GIMMI et al., "Breast Cancer-Associated Antigen, DF3/MUC1, Induces Apoptosis Of Activated Human T Cells", *Nature Medicine*, Vol. 2(12):1367-1370, (1996)
A43	YEH et al., "Expression of B7-1 By Pam 212 Squamous Cell Carcinoma Enhances Tumor Cell Intractions With, Dendritic Epidermal T Cells But Does Not Affect In Vivo Tumor Growth", *J. Invest. Dermatol.*, Vol. 109:728-733, (1997)

EXAMINER	**DATE CONSIDERED**
	4/9/02

* **EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.**